Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RNK08954 in KRAS G12D-mutant advanced gynecologic tumors
CTR20263173Phase 2Active
- Sponsor
- Ranok Therapeutics
- Start
- Aug 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RNK08954 in gynecological cancer, ovarian cancer, endometrial cancer (EC), Cervical Cancer (CC), sponsored by Ranok Therapeutics. Started Aug 2026; status: active.
02
Drugs
RNK08954
03
Conditions
gynecological cancerovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20263173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263173.